Nanoscale.:具有持续药物释放能力的聚(ε-己内酯)纳米载体:用于长期青光眼治疗!

2017-08-13 cuiguizhong MedSci原创

台湾桃园长庚大学生物化学与生物医学工程研究所的Lee CH, 近日在Nanoscale 杂志上发表了一项有趣的工作,标题为"Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment",他们开发持续和长期释放青光眼药物毛果芸香碱

台湾桃园长庚大学生物化学与生物医学工程研究所的Lee CH, 近日在Nanoscale 杂志上发表了一项有趣的工作,标题为"Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment",他们开发持续和长期释放青光眼药物毛果芸香碱的聚(ε-己内酯)纳米粒子(PCL NPs)。

青光眼是伴有眼压升高(IOP)的眼睛相关疾病,眼压升高会引起视神经损伤,进而导致视力丧失甚至失明。虽然用眼药水治疗青光眼可能会降低眼压,但眼药水有一些限制,例如患者依从性差和持续时间短。

开发持续和长期释放药物的青光眼药物载体具有重要的意义,为此,他们合成了能够携带毛果芸香碱的聚(ε-己内酯)纳米粒子(PCL NPs),其中毛果芸香碱是一种广泛用于治疗干眼症和青光眼的药物。他们制备了两种类型的PCL NP,即纳米球(NSs)和纳米胶囊(NC)。纳米球(NSs)是能够将固体物质吸收的固体球体,而纳米胶囊(NC)是用于封装药物的中空球形结构。此外,他们还研究了PCL NPs的囊泡结构对药物负载效率和释放的影响。

他们发现, PCL NC中毛果芸香碱的携带量约为PCL NSs的3倍。同时,含有毛果芸香碱的PCL NC(PILO-PCL NC)具有持续的药物释放特征。动物活体实验显示,在兔子中用含有毛果芸香碱的PCL NPs,观察到有效的药理学反应,即IOP降低和瞳孔收缩。同时研究显示, PILO-PCL NC具有长期治疗能力,在用其治疗42天后,发现可以减轻眼高压引起的角膜和视网膜损伤。体内研究的结果也表明,PCL NCs对治疗青光眼患者的慢性高眼压有很好的疗效。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645437, encodeId=8cfa164543e94, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 03 15:42:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075751, encodeId=3e5020e575157, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon May 28 10:42:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793653, encodeId=8bf01e93653e7, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Nov 18 15:42:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233286, encodeId=aa132332866f, content=学习了,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 13 23:09:54 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233268, encodeId=cf5323326899, content=体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Aug 13 22:27:29 CST 2017, time=2017-08-13, status=1, ipAttribution=)]
    2018-02-03 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645437, encodeId=8cfa164543e94, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 03 15:42:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075751, encodeId=3e5020e575157, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon May 28 10:42:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793653, encodeId=8bf01e93653e7, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Nov 18 15:42:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233286, encodeId=aa132332866f, content=学习了,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 13 23:09:54 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233268, encodeId=cf5323326899, content=体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Aug 13 22:27:29 CST 2017, time=2017-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645437, encodeId=8cfa164543e94, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 03 15:42:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075751, encodeId=3e5020e575157, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon May 28 10:42:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793653, encodeId=8bf01e93653e7, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Nov 18 15:42:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233286, encodeId=aa132332866f, content=学习了,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 13 23:09:54 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233268, encodeId=cf5323326899, content=体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Aug 13 22:27:29 CST 2017, time=2017-08-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645437, encodeId=8cfa164543e94, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 03 15:42:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075751, encodeId=3e5020e575157, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon May 28 10:42:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793653, encodeId=8bf01e93653e7, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Nov 18 15:42:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233286, encodeId=aa132332866f, content=学习了,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 13 23:09:54 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233268, encodeId=cf5323326899, content=体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Aug 13 22:27:29 CST 2017, time=2017-08-13, status=1, ipAttribution=)]
    2017-08-13 清风拂面

    学习了,受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1645437, encodeId=8cfa164543e94, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 03 15:42:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075751, encodeId=3e5020e575157, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon May 28 10:42:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793653, encodeId=8bf01e93653e7, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Nov 18 15:42:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233286, encodeId=aa132332866f, content=学习了,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 13 23:09:54 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233268, encodeId=cf5323326899, content=体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun Aug 13 22:27:29 CST 2017, time=2017-08-13, status=1, ipAttribution=)]
    2017-08-13 有备才能无患

    体内研究的结果也表明,PCLNCs对治疗青光眼患者的慢性高眼压有很好的疗效。

    0

相关资讯

Exp Parasitol.:两种商业性常用于降低眼压的眼药水具有抗棘阿米巴原虫活性!

西班牙拉古纳大学热带病与公共卫生大学研究所的Sifaoui I近日在Exp Parasitol杂志上发表了一项有趣的工作,标题为"Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure."他们发现有两种常用于降低眼压的眼药水具有抗棘阿米巴

我国微导管辅助的360°小梁切开术专家共识(2017年)

微导管辅助的360。小梁切开术是在黏小管成形术基础上发展起来的新术式,是在直视下将发光微导管准确插入Schlernm管内,实现360。穿通,然后利用微导管将Schlemm管内壁及小梁网360。切开。该技术可避免常规手术切开刀未进入Schlemm管而造成假道形成等并发症的发生”。 为了临床能够正确开展微导管辅助的360。小梁切开术,中华医学会眼科学分会青光眼学组全体委员通过认真讨论,对手术提出以下共

J Glaucoma. :饮水测试的眼内压峰值可以预测青光眼视觉发展情况!

哥伦比亚大学医学中心眼科的De Moraes CG在J Glaucoma.发表了一项工作,他们这项工作的目的是测试他们提出的一个假设:在压力测试时[饮水测试(WDT)],眼内压(IOP)峰值可以用来预测经过治疗的原发性开角型青光眼(POAG)患者未来视野恢复过程中的风险。

我国房水流出通路重建术专家共识(2017年)

为了临床能够正确开展房水流出通路重建术,中华医学会眼科学分会青光眼学组全体委员通过认真讨论,对手术提出该共识意见。

Expert Rev Ophthalmol:BDNF/TrkB信号通路在视觉系统中的作用:对青光眼的治疗意义!

美国奥古斯塔大学眼科系的Bollinger KE教授近日在Korean J Ophthalmol杂志上发表了一篇综述,系统的阐述了BDNF / TrkB信号通路在青光眼发展过程的作用,并对其治疗提出展望。

Nat Genet:12 万人基因测序找到预防青光眼的突变基因

青光眼作为当今全球不可逆失明的主要原因,深深的困扰着许多人。近日,一项迄今为止规模最大的青光眼国际研究合作有可能为治疗和预防青光眼指明了方向。这项涉及全世界 6 大洲 36 个国家 12 万多人的研究,用深度基因测序的方法,发现了一种可以预防青光眼的突变基因。这项研究结果最近发表在《自然》子刊《Nature Genetics》期刊上。